Latest Articles
Analysis of Tumor-Associated Macrophages (TAM) Using Cluster of Differentiation 68 (CD68) Immunohistochemical Marker in Endometrial Carcinoma - Cureus
Analysis of Tumor-Associated Macrophages (TAM) Using Cluster of Differentiation 68 (CD68) Immunohistochemical Marker in Endometrial Carcinoma Cureus
Published: May 31, 2026, 4:44 p.m.
Acrivon Therapeutics’ SWOT analysis: stock shows promise in cancer pipeline - Investing.com UK
Acrivon Therapeutics’ SWOT analysis: stock shows promise in cancer pipeline Investing.com UK
Published: May 21, 2026, 8:34 p.m.
Acrivon Therapeutics’ SWOT analysis: stock shows promise in cancer pipeline - Investing.com
Acrivon Therapeutics’ SWOT analysis: stock shows promise in cancer pipeline Investing.com
Published: May 21, 2026, 2:57 p.m.
Pfizer targets VEGF bispecific white space | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Pfizer targets VEGF bispecific white space | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
Published: May 21, 2026, 12:46 p.m.
Compartment-based image analysis will boost endometriosis detection - AuntMinnieEurope
Compartment-based image analysis will boost endometriosis detection AuntMinnieEurope
Published: May 1, 2026, 9:18 p.m.
Growth Patterns, Market Segment Analysis, and Competitor Approaches Influencing the Endometriosis Market - openPR.com
Growth Patterns, Market Segment Analysis, and Competitor Approaches Influencing the Endometriosis Market openPR.com
Published: April 20, 2026, 8:34 a.m.
Endometriosis Drugs Sales Market Analysis By Application, - openPR.com
Endometriosis Drugs Sales Market Analysis By Application, openPR.com
Published: April 17, 2026, 11:10 a.m.
SGO 2026 – GSK bucks the B7-H4 trend | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
SGO 2026 – GSK bucks the B7-H4 trend | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
Published: April 13, 2026, 12:32 p.m.
SGO 2026 – BioNTech’s Enhertu me-too comes up short | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
SGO 2026 – BioNTech’s Enhertu me-too comes up short | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
Published: April 13, 2026, 10:30 a.m.
Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as Highly Expressed, Clinically Relevant Target for Gynecologic Cancers - National Today
Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as Highly Expressed, Clinically Relevant Target for Gynecologic Cancers National Today
Published: April 10, 2026, 4:35 p.m.
Link copied to clipboard!